hotspot -WSS

hotspot

author：knowledge 2025-10-02 11:09:37 - browse：73841

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Abortion pill case raises question: who can sue the FDA?

entertainment

WSS

Donor acceptance rates hint at racial, gender bias in heart transplants: study

There's no autism epidemic. It's an autism diagnosis epidemic

Decaf coffee targeted by food safety group under obscure FDA rule

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Faced with fears of OxyContin misuse, sales reps touted its safety

Newly revealed memo details efforts to keep Trump in power following election loss

explore

hotspot

knowledge

Sports medicine is finally prioritizing gender equality

Some of the ways extreme heat will change life as we know it

Jerome Adams on the need for new antivirals for Covid

CDC overhauls leadership of center that led response to Covid

Cancer drug shortages should be causing more outrage

Maui funeral service workers on devastation of fires: 'I'm in shock'

Sports medicine is finally prioritizing gender equality

FDA's naming rule on biosimilars has undermined competition

United colonoscopy coverage change 'may cost lives,' doctors say

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

focus

Kim Kardashian sparks debate on benefits of full

Roche subsidiary Foundation Medicine opens new headquarters

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Faced with fears of OxyContin misuse, sales reps touted its safety

Genentech weighs delaying cancer therapy after drug pricing law

FDA's naming rule on biosimilars has undermined competition

explore

focus

entertainment

focus